Karen S. Lynch - Feb 21, 2022 Form 4 Insider Report for CVS HEALTH Corp (CVS)

Role
President and CEO, Director
Signature
/s/ Karen S. Lynch
Stock symbol
CVS
Transactions as of
Feb 21, 2022
Transactions value $
$0
Form type
4
Date filed
2/23/2022, 03:29 PM
Previous filing
Dec 20, 2021
Next filing
Apr 5, 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CVS Common Stock Award $0 +258K +373.17% $0.00 327K Feb 21, 2022 Direct F1
holding CVS Common Stock (By Trust) 94.4K Feb 21, 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding CVS Stock Appreciation Rights 193K Feb 21, 2022 Common Stock 193K $45.91 Direct F2
holding CVS Stock Appreciation Rights 94K Feb 21, 2022 Common Stock 94K $37.91 Direct F3
holding CVS Stock Option 242K Feb 21, 2022 Common Stock 242K $54.19 Direct F4
holding CVS Stock Option 211K Feb 21, 2022 Common Stock 211K $58.34 Direct F5, F6
holding CVS Stock Option 225K Feb 21, 2022 Common Stock 225K $74.30 Direct F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares earned by the reporting person pursuant to certain performance stock units (the "PSUs"), which were granted to the reporting person under the Issuer's Aetna Inc. 2010 Incentive Compensation Plan (the "Aetna Plan") on June 5, 2019. The PSUs were earned based on the attainment of certain performance metrics, which performance metrics were certified by the Management and Planning Committee of the Board of Directors of the Issuer on February 21, 2022.
F2 Represents unvested Aetna Inc. Stock Appreciation Rights ("SARs") granted under the Aetna Plan on February 17, 2017 that were converted into CVS Health SARs pursuant to the terms of the CVS/Aetna Merger Agreement. These SARs vest in two substantially equal annual installments beginning on February 17, 2019.
F3 Represents unvested SARs granted under the Aetna Plan on February 19, 2016 that were converted into CVS Health SARs pursuant to the terms of the CVS/Aetna Merger Agreement. These SARs vested on February 19, 2019.
F4 Option became exercisable in four equal annual installments, commencing 4/1/2020.
F5 The number of shares subject to the option were calculated using a 30-day average price.
F6 Options became exercisable in four equal installments, commencing 4/1/2021.
F7 Option becomes exercisable in four equal installments, commencing 4/1/2022.